Shots:

• The government of Saskatchewan will implement a switching or transitioning policy to expand the use of biosimilar medicines under its public drug programs and reinvest the savings to support patient access to public drug coverage and new drug benefits
• Saskatchewan joined 5 provinces and 1 territory in implementing a biosimilar switching policy, allowing for reference products to be switched out for biosimilars and lowering drug costs for the province’s public health plan
• Patients who are covered by the Saskatchewan Drug Plan and received biological drugs will have to switch to a biosimilar version of their medicine by April 2023 to treat conditions incl. arthritis, diabetes, IBD & psoriasis

Ref: Saskatchewan | Image: Saskatchewan